Goldstein Advisors LLC Has $530,000 Stake in Exact Sciences Corporation (NASDAQ:EXAS)

Goldstein Advisors LLC boosted its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 113.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,254 shares of the medical research company's stock after purchasing an additional 6,523 shares during the quarter. Goldstein Advisors LLC's holdings in Exact Sciences were worth $530,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in EXAS. Robeco Institutional Asset Management B.V. raised its holdings in shares of Exact Sciences by 298.6% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 148,629 shares of the medical research company's stock worth $6,434,000 after buying an additional 111,343 shares in the last quarter. Global Assets Advisory LLC acquired a new stake in shares of Exact Sciences in the 1st quarter valued at $280,000. FORM Wealth Advisors LLC acquired a new stake in shares of Exact Sciences in the 1st quarter valued at $342,000. Asset Management One Co. Ltd. increased its stake in shares of Exact Sciences by 4.5% in the 1st quarter. Asset Management One Co. Ltd. now owns 68,500 shares of the medical research company's stock valued at $2,965,000 after buying an additional 2,949 shares during the period. Finally, Walkner Condon Financial Advisors LLC increased its stake in shares of Exact Sciences by 10.7% in the 1st quarter. Walkner Condon Financial Advisors LLC now owns 9,430 shares of the medical research company's stock valued at $418,000 after buying an additional 913 shares during the period. Institutional investors own 88.82% of the company's stock.

Insider Buying and Selling

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $53.20, for a total value of $170,612.40. Following the sale, the director now owns 72,759 shares in the company, valued at $3,870,778.80. This represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is currently owned by corporate insiders.

Exact Sciences Stock Up 3.6%

Shares of Exact Sciences stock traded up $1.84 during trading on Friday, reaching $53.65. The stock had a trading volume of 9,017,373 shares, compared to its average volume of 2,577,911. The company has a market capitalization of $10.12 billion, a price-to-earnings ratio of -9.74, a P/E/G ratio of 39.33 and a beta of 0.98. The stock has a fifty day moving average price of $52.83 and a two-hundred day moving average price of $51.51. Exact Sciences Corporation has a 52 week low of $39.97 and a 52 week high of $72.83. The company has a current ratio of 2.73, a quick ratio of 2.38 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. The company had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. During the same period in the previous year, the company posted ($0.60) earnings per share. The company's quarterly revenue was up 10.9% compared to the same quarter last year. Sell-side analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Barclays lowered their target price on Exact Sciences from $75.00 to $65.00 and set an "overweight" rating for the company in a research note on Tuesday. Evercore ISI lifted their price objective on Exact Sciences from $60.00 to $66.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Robert W. Baird lifted their price objective on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Royal Bank Of Canada lifted their price objective on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Finally, Mizuho initiated coverage on Exact Sciences in a research note on Thursday, April 10th. They set an "outperform" rating and a $60.00 price objective for the company. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $70.40.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.